Prediction: Eli Lilly Stock Will Hit This Price by the End of 2026
Eli Lilly's next leg of growth may have less to do with how well its weight loss drugs work and more to do with how many people can finally get them.
Overview
Most coverage of Eli Lilly (NYSE: LLY) focuses on one number: how much weight its drugs help people take off. The question that matters more for the rest of 2026 is a different one. How many people can now access those drugs in the first place? That shift, from a science story to a drug access story, is the reason I think the stock has room to climb before the year is out.
In April, the FDA approved Foundayo (orforglipron), the first GLP-1 pill for weight management that a person can take at any time of day with no food or water restrictions. That last detail carries more weight than it seems. Injectable treatments need refrigeration, needles, and a comfort with self-injection that keeps a lot of would-be patients on the sidelines. A daily pill strips away those barriers. Eli Lilly started shipping Foundayo through its own LillyDirect platform within days of approval, with self-pay pricing that starts near $149 a month for the lowest dose.
Details
For newer investors, here is why the format is such a big deal. An oral drug is cheaper to make and far simpler to ship at scale than an injection. That means Eli Lilly can serve markets where cold-chain logistics have made injectable versions hard to distribute, including large parts of the world that the current obesity drug boom has barely reached.
Source
Originally published at www.fool.com.